An Epidemiological Study of Acute Coronary Syndromes in The Greek Population
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndromes
- Sponsor
- AstraZeneca
- Enrollment
- 418
- Locations
- 1
- Primary Endpoint
- To evaluate the proportion of patients who are on target for LDL-C according to the 2004-updated NCEP ATPIII guidelines as calculated within the first 24-hours of hospital admission for an ACS.
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index event, as well as to depict the current management practices and outcomes of these clinical conditions in Greece.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of an ACS (STEMI, NSTEMI, UA).
- •Informed Consent
Exclusion Criteria
- •Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at the study sites).
- •Participation in other clinical study in period between the index event and 6- month follow-up assessment with the exception of registering in registries or surveys not influencing the management of the ACS.
Outcomes
Primary Outcomes
To evaluate the proportion of patients who are on target for LDL-C according to the 2004-updated NCEP ATPIII guidelines as calculated within the first 24-hours of hospital admission for an ACS.
Time Frame: first visit - 1st day (cross-sectional part)
To estimate the proportion of patients enrolled in the cross-sectional part of the study that experiences a Major Adverse Cardiovascular Event (MACE) within a 6-month follow-up period.
Time Frame: follow up visit - 6th month (prospective part)
Secondary Outcomes
- To estimate the proportion of patients admitted to the hospital with STEMI, NSTEMI and unstable angina.(first visit - 1st day (cross-sectional part))
- To estimate the "pain-to-door-time" throughout different regions in Greece.(first visit - 1st day (cross-sectional part))
- To estimate the time to first MACE and to estimate CV, non-CV and all cause mortality within the 6-month period following the index ACS event.(follow up visit - 6th month (prospective part))